Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Barrick Gold Corp (B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Barrick Gold Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Barrick Gold Corp trades at $35.64 (market cap $61.76B). The key difference: Barrick Gold Corp is far larger — about 13.8× ACADIA Pharmaceuticals Inc.'s market cap, and Barrick Gold Corp pays a 1.9% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | B | |
|---|---|---|
Market Cap | $4.49B | $61.76B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $52.97 |
52-Week Low | $20.06 | $20.73 |
Enterprise Value | $3.69B | $59.35B |
Dividend Yield | — | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Barrick Mining (B) trades at $36.86, down 3.55% over 24 hours, with technical indicators signaling a bearish trend. The company demonstrates strong fundamentals with a P/E of 10.07, net income margin of 32.14%, and consistent earnings beats in recent quarters. Revenue surged to $17.0B in 2025, up from $12.9B in 2024, while cash flow from operations improved to $7.7B. A dividend of $0.18 per share is scheduled for payment on June 15, 2026.
The stock presents a value opportunity with a consensus price target of $51.33, implying 39% upside, supported by 68% analyst buy ratings. Risks include gold price volatility and operational execution challenges. Strong cash flow generation and low debt levels provide a solid foundation for growth, though near-term technical weakness may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
